Clinical Trial: Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06943586) titled 'Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing' on April 03.

Brief Summary: The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.

Study Start Date: April 09

Study Type: INTERVENTIONAL

Condition: Stroke Transient Ischemic Attack (TIA)

Intervention: GENETIC: CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)

CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medic...